UA79460C2 - Benzoxazinone derived compounds, method for their preparation, intermediate, medicaments containing these compounds - Google Patents

Benzoxazinone derived compounds, method for their preparation, intermediate, medicaments containing these compounds Download PDF

Info

Publication number
UA79460C2
UA79460C2 UA20041109155A UA20041109155A UA79460C2 UA 79460 C2 UA79460 C2 UA 79460C2 UA 20041109155 A UA20041109155 A UA 20041109155A UA 20041109155 A UA20041109155 A UA 20041109155A UA 79460 C2 UA79460 C2 UA 79460C2
Authority
UA
Ukraine
Prior art keywords
oxo
piperidin
monosubstituted
optionally
oxazin
Prior art date
Application number
UA20041109155A
Other languages
English (en)
Ukrainian (uk)
Inventor
Jover Antoni Torrens
Castrillo Perez Aurelio
Constansa Jordi Frigola
Prio Josep Mas
Zueras Alberto Dordal
Fisas Escasany Angeles
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of UA79460C2 publication Critical patent/UA79460C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
UA20041109155A 2002-04-09 2003-08-04 Benzoxazinone derived compounds, method for their preparation, intermediate, medicaments containing these compounds UA79460C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200200813A ES2193875B2 (es) 2002-04-09 2002-04-09 Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.
PCT/EP2003/003629 WO2003084952A1 (en) 2002-04-09 2003-04-08 Benzoxazinone-derived compounds, their preparation und use as medicaments

Publications (1)

Publication Number Publication Date
UA79460C2 true UA79460C2 (en) 2007-06-25

Family

ID=28686085

Family Applications (1)

Application Number Title Priority Date Filing Date
UA20041109155A UA79460C2 (en) 2002-04-09 2003-08-04 Benzoxazinone derived compounds, method for their preparation, intermediate, medicaments containing these compounds

Country Status (29)

Country Link
US (3) US7056914B2 (no)
EP (2) EP1497285B1 (no)
JP (1) JP2005529866A (no)
KR (1) KR20050008679A (no)
CN (1) CN1659164A (no)
AR (2) AR039256A1 (no)
AT (2) ATE489382T1 (no)
AU (2) AU2003222804A1 (no)
BR (1) BR0309083A (no)
CA (1) CA2481701A1 (no)
DE (2) DE60335094D1 (no)
DK (1) DK1500654T3 (no)
EC (1) ECSP045353A (no)
ES (3) ES2193875B2 (no)
HK (1) HK1069820A1 (no)
HR (1) HRP20040919A2 (no)
IL (1) IL164442A0 (no)
IS (1) IS7491A (no)
MA (1) MA27692A1 (no)
MX (1) MXPA04009889A (no)
NO (1) NO20044322L (no)
NZ (1) NZ536167A (no)
PL (1) PL372537A1 (no)
PT (1) PT1500654E (no)
RU (1) RU2004133041A (no)
TN (1) TNSN04203A1 (no)
UA (1) UA79460C2 (no)
WO (2) WO2003084952A1 (no)
ZA (1) ZA200408275B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2193875B2 (es) * 2002-04-09 2005-03-01 Laboratorios Del Dr. Esteve, S.A. Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.
ES2222833B1 (es) * 2003-07-30 2006-03-01 Laboratorios Del Dr. Esteve, S.A. Compuestos piperidinicos 1,4-disustituidos, su preparacion y su uso como medicamentos.
ES2228268B1 (es) * 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
ES2228267B1 (es) * 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
WO2005090340A1 (ja) * 2004-03-22 2005-09-29 Banyu Pharmaceutical Co., Ltd. ピペリジン-1-カルボキサミド誘導体
US8147853B2 (en) 2005-02-15 2012-04-03 The Procter & Gamble Company Personal care compositions containing hydrophobically modified non-platelet particles
JP2008523110A (ja) * 2005-03-21 2008-07-03 ザ プロクター アンド ギャンブル カンパニー 視覚的に区別できる相を含む多相パーソナルケア組成物
US7820609B2 (en) 2005-04-13 2010-10-26 The Procter & Gamble Company Mild, structured, multi-phase personal cleansing compositions comprising density modifiers
WO2006113118A1 (en) * 2005-04-13 2006-10-26 The Procter & Gamble Company Structured multi-phased personal care composition comprising branched anionic surfactants
ITMI20050909A1 (it) * 2005-05-19 2006-11-20 Acraf Uso di un benzoil derivato dal 3-ammino-carbazolo per la produzione di un farmaco per il trattamento di un disturbo associato alla produzione di prostaglandina e2-pge2-
US20120015009A9 (en) * 2005-06-07 2012-01-19 The Procter & Gamble Company Multi-phased personal care composition comprising a blooming perfume composition
ITMI20051523A1 (it) * 2005-08-03 2007-02-04 Acraf Composto del 3-ammino-carbazolo composizione farmaceutica che lo contiene e metodo per prepararlo
CN101326106A (zh) * 2005-12-08 2008-12-17 宝洁公司 包括邻近表面形貌定位的模内标签的容器
US20070167338A1 (en) * 2006-01-09 2007-07-19 Mchugh Colin M Multiphase personal care compositions comprising beads
US8104616B2 (en) 2006-02-11 2012-01-31 The Procter & Gamble Company Clamshell package for holding and displaying consumer products
US8153144B2 (en) * 2006-02-28 2012-04-10 The Proctor & Gamble Company Stable multiphase composition comprising alkylamphoacetate
CA2660799C (en) * 2006-08-14 2013-03-19 Council Of Scientific & Industrial Research Pyrrolo[2,1-c][1,4]benzodiazepine hybrids and a process for the preparation thereof
EP1902733A1 (en) * 2006-09-19 2008-03-26 Laboratorios Del Dr. Esteve, S.A. Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity
CL2007003044A1 (es) * 2006-10-24 2008-07-04 Wyeth Corp Compuestos derivados de benzoxazina; composicion farmaceutica que los comprende; y uso para el tratamiento de un trastorno psicotico, bipolar, depresivo y abuso o dependencia de sustancias entre otros.
US20090028808A1 (en) * 2007-07-27 2009-01-29 The Procter & Gamble Company Personal care article for sequentially dispensing compositions with variable concentrations of partitioned benefit or suspended benefit agents
US20090028809A1 (en) * 2007-07-27 2009-01-29 Jonathan Robert Cetti Personal care article for sequentially dispensing compositions with variable concentrations of hydrophobic benefit materials
US20090029900A1 (en) * 2007-07-27 2009-01-29 The Procter & Gamble Company Personal care article for sequentially dispensing compositions with distinct fragrance characters
US7733945B2 (en) * 2008-03-18 2010-06-08 On-Ramp Wireless, Inc. Spread spectrum with doppler optimization
US20090275574A1 (en) * 2008-05-05 2009-11-05 Astrazeneca Ab Novel compounds-300
EP2404902A1 (en) * 2009-03-05 2012-01-11 Shionogi&Co., Ltd. Piperidine and pyrrolidine derivatives having npy y5 receptor antagonism
CN110684043B (zh) * 2019-08-13 2022-09-06 温州大学 一种c-n轴手性芳胺化合物及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09500134A (ja) * 1993-07-16 1997-01-07 メルク エンド カンパニー インコーポレーテッド ベンゾオキサジノンおよびベンゾピリミジノンピペリジニル早産防止オキシトシン受容体拮抗剤
US5760054A (en) 1994-04-14 1998-06-02 Merck & Co., Inc. Alpha IC adrenergic receptor antagonists
AU7692996A (en) 1995-12-01 1997-06-27 Ciba-Geigy Ag Receptor antagonists
WO1997019682A1 (en) 1995-12-01 1997-06-05 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
WO1997025992A1 (en) 1996-01-16 1997-07-24 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
CA2249601A1 (en) 1996-04-03 1997-10-23 Thorsten E. Fisher Inhibitors of farnesyl-protein transferase
CA2273102A1 (en) 1996-12-03 1998-06-11 Banyu Pharmaceutical Co., Ltd. Urea derivatives
WO1998035957A1 (en) 1997-02-14 1998-08-20 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
AU6309698A (en) 1997-03-12 1998-09-29 Banyu Pharmaceutical Co., Ltd. Drugs containing aminopyridine derivatives as the active ingredient
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
EP1119543B1 (en) 1998-10-07 2004-12-15 Ortho-McNeil Pharmaceutical, Inc. N-aralkylaminotetralins as ligands for the neuropeptide y y5 receptor
WO2001007409A1 (en) 1999-07-23 2001-02-01 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
US6348472B1 (en) 1999-08-26 2002-02-19 Bristol-Myers Squibb Company NPY antagonists: spiroisoquinolinone derivatives
SE9904652D0 (sv) * 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
WO2001064675A1 (en) 2000-03-03 2001-09-07 Novartis Ag Condensed thiazolamines and their use as neuropeptide y5 antagonists
WO2002094825A1 (fr) 2001-05-22 2002-11-28 Banyu Pharmaceutical Co., Ltd. Nouveau derive de spiropiperidine
PL367983A1 (en) * 2001-08-07 2005-03-21 Banyu Pharmaceutical Co, Ltd. Spiro compounds
ES2193875B2 (es) * 2002-04-09 2005-03-01 Laboratorios Del Dr. Esteve, S.A. Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.

Also Published As

Publication number Publication date
MXPA04009889A (es) 2005-08-16
IS7491A (is) 2004-10-06
CA2481701A1 (en) 2003-10-16
US7514429B2 (en) 2009-04-07
DK1500654T3 (da) 2006-06-06
ES2193875A1 (es) 2003-11-01
EP1497285B1 (en) 2010-11-24
US20060128701A1 (en) 2006-06-15
ES2193875B2 (es) 2005-03-01
US20040067941A1 (en) 2004-04-08
EP1500654A1 (en) 2005-01-26
ATE316966T1 (de) 2006-02-15
EP1497285A1 (en) 2005-01-19
ES2258219T3 (es) 2006-08-16
HRP20040919A2 (en) 2005-04-30
CN1659164A (zh) 2005-08-24
KR20050008679A (ko) 2005-01-21
JP2005529866A (ja) 2005-10-06
MA27692A1 (fr) 2006-01-02
ZA200408275B (en) 2006-04-26
BR0309083A (pt) 2005-04-19
TNSN04203A1 (en) 2007-03-12
AR039256A1 (es) 2005-02-16
IL164442A0 (en) 2005-12-18
RU2004133041A (ru) 2005-09-10
US7041665B2 (en) 2006-05-09
ECSP045353A (es) 2005-01-28
AU2003216934A1 (en) 2003-10-20
AR048567A1 (es) 2006-05-10
DE60335094D1 (de) 2011-01-05
WO2003084952A1 (en) 2003-10-16
DE60303440T2 (de) 2006-10-26
US7056914B2 (en) 2006-06-06
ATE489382T1 (de) 2010-12-15
ES2356815T3 (es) 2011-04-13
AU2003222804A1 (en) 2003-10-20
EP1500654B1 (en) 2006-02-01
WO2003084939A1 (es) 2003-10-16
PT1500654E (pt) 2006-06-30
NZ536167A (en) 2006-06-30
PL372537A1 (en) 2005-07-25
DE60303440D1 (de) 2006-04-13
US20040058920A1 (en) 2004-03-25
HK1069820A1 (en) 2005-06-03
NO20044322L (no) 2004-10-12

Similar Documents

Publication Publication Date Title
UA79460C2 (en) Benzoxazinone derived compounds, method for their preparation, intermediate, medicaments containing these compounds
JP5823476B2 (ja) Nk1アンタゴニストとしてのピロリジンおよびピペリジンの誘導体
EP2038268B1 (en) Carbonylated (aza)cyclohexanes as dopamine d3 receptor ligands
KR101062513B1 (ko) 5ht2/d3 조절제로서의 벤조일-피페리딘 유도체
EP2271405B1 (en) Nip thiazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
US20050054850A1 (en) Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
US20060094720A1 (en) NK1 antagonists
JP2008531679A (ja) オキシトシンアンタゴニストとしての1,2,4−トリアゾール誘導体とその使用
KR20030003758A (ko) 치환된 1-아미노알킬-락탐 및 무스카린성 수용체길항제로서의 용도
AU686400B2 (en) Serotonin 5-HT-1A and dopamin D-2 receptor ligands
HU229709B1 (en) Piperazinyilpiperidine derivatives as chemokine receptor antagonists
EP0029707B1 (en) Novel piperidine derivatives, method for the preparation thereof and pharmaceutical compositions containing them
EA022776B1 (ru) Арилсульфонамиды для лечения заболеваний цнс
US7384957B2 (en) 3,4-dihydro-1H-isoquinolin-2-yl-derivatives
JP5763211B2 (ja) Nk3アンタゴニストとしてのピロリジン誘導体
WO2001025199A1 (fr) Composes d'uree, procede de production et d'utilisation de ces derniers
JP2001122784A (ja) 1−[(1−置換−4−ピペリジニル)メチル]−4−ピペリジン誘導体からなる医薬
WO2002055497A1 (en) Aryl piperidine derivatives as inducers of ldl-receptor expression
KR20110059749A (ko) 선택적 11-베타-하이드록시스테로이드 디하이드로게나제 타입 1 억제제로서 융합된 피롤리디노-사이클로프로판 유도체들
JP2004277320A (ja) 1,4−ジ置換ピペリジン誘導体およびそれを含有する医薬組成物
SI9011538A (sl) Novi 1-oksa-2-okso-8-azaspiro/4,5/dekanski derivati, farmacevtski pripravki, ki jih vsebujejo, in postopek za njihovo pripravo
WO2004032856A2 (en) Compounds
JP2001172260A (ja) ウレア化合物、その製造法および用途